IACS-13909

IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1) . IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK) -dependent cancers[1].

Product Specifications

CAS Number

[2160546-07-4]

UNSPSC

12352005

Target

Phosphatase; SHP2

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iacs-13909.html

Concentration

10mM

Purity

99.97

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

NC1(C)CCN(C2=CN=C3C(NN=C3C4=CC=CC(Cl)=C4Cl)=N2)CC1

Molecular Formula

C17H18Cl2N6

Molecular Weight

377.27

References & Citations

[1]Yuting Sun, et al. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Res. 2020 Nov 1;80 (21) :4840-4853.